Romatoid artrit tedavisinde metotreksat’ın reçetelenmesi ve izlemine yönelik gereksinimler ve hastanın kendi kendine bakım süreci ile ilgili konsensüs geliştirilmesi

Year 2013, Issue: 1, 1 - 24, 01.01.2013

Aygin Bayraktar-ekincioğlu

Abstract

Bu çalışma, romatoid artrit tedavisinde metotreksat kullanımı ile ilgili olarak romatoloji uzmanlarının olası sorunlarını ve endişelerini ortaya çıkarmak ve bunun sonucunda iyi uygulama standartlarını belirleyen önerileri elde etmeyi amaçlamaktadır. Fikir birliğine ulaşabilmek için kullanılan yöntemlerden 4 tekrarlı Delphi tekniği, İskoçya’daki 38 romatoloji uzmanı ile gerçekleştirilmiştir. Katılımcıların fikirlerini, toplamda 42 sorudan oluşan ankette ve 9-kademeli Likert skalası kullanarak 1: Hiçbir şekilde katılmıyorum - 9: Tamamıyla katılıyorum ifade etmeleri istenmiştir. Her anket tekrarının sonucu analiz edilerek, her soruya verilen cevap katılımcıların sayısı ve yüzdesi ve de grup medyan skoru olarak belirtilmiştir. Çalışma, romatoloji uzmanları arasında metotreksat kullanım uygulamaları açısından farklılıklar olduğunu ortaya koymuştur. Katılımcıların metotreksat başlangıç dozu, doz arttırımları, izlem parametreleri açısından benzer şekilde hareket ettikleri gözlense de; izleme dair hususları, uzman hemşire dışında, diğer bir sağlık personeline devretme konusunda istekli olmadıkları belirtilmiştir. Diğer taraftan, romatoloji uzmanları bazı metotreksat yan etkilerinin izlemini hastalara bırakma fikrini desteklemektedir. Romatoloji uzmanlarının metotreksat kullanan hastaların izlemi konusundaki kriterlerindeki farklı tercihleri ve yerel rehberlerin değişkenlikleri, bakımın sağlanması konusunda farklı uygulamalara yol açmaktadır. Diğer sağlık çalışanlarının örneğin, aile hekimleri ve eczacılar multidisipliner olarak ortaklaşa bakım sürecinde rollerinin ve sorumluluklarının farkına varılması, güvenli ve etkin ilaç kullanımına, yakın hasta izlemine ve bakımın sürekliliğinin sağlanmasına yol açacaktır.

Keywords

metotreksat, romatoid artrit, Delphi tekniği, kendi-kendine bakım

Consensus Development on Requirements in Methotrexate Prescribing, Monitoring and Patient’s Self-Care in the Treatment of Rheumatoid Arthritis

Abstract

The aim of the study was to identify potential problems and concerns of rheumatology specialists regarding methotrexate therapy and to obtain recommendations about good practice standards for methotrexate use in the treatment of rheumatoid arthritis. Four rounds of the Delphi technique were used for a consensus development among 38 rheumatology specialists in Scotland. The participants were asked to indicate their opinion for 42 questions in a total questionnaire using a 9-point Likert scale 1: strongly disagree to 9: strongly agree . The results of each round were analyzed and presented in numbers and percentages of participants answering for each questions and group median interquartile range scores. The survey revealed that there were variations in the practice of rheumatology specialists in the use of methotrexate therapy. The participants were practicing in a similar way in terms of methotrexate initial dose and dose increments, monitoring parameters; however they were not willing to delegate monitoring issues to other health care professionals, except nurse specialist. On the other hand, the rheumatologists supported the idea of delegation some of the monitoring issues regarding methotrexate side effects to the patients. Differences in preferences among rheumatology specialists on the criteria for monitoring patients receiving methotrexate treatment and the variability in local guidelines has led to different practices in the provision of care. Recognition of roles and delegation of certain responsibilities to the other health providers such as general practitioners and pharmacists in a multidisciplinary shared care would yield to safe and effective drug use, close monitoring, and continuity of care.

Keywords

methotrexate, rheumatoid arthritis, Delphi technique, self-care

References

• Lee, D.M., Weinblatt, M.E. Rheumatoid arthritis, Lancet, 358,903-11 (2001).
• Gray, R., Muirie, J. Needs Assessment Report: Rheumatoid Arthritis in adults: Gain- ing health from effective treatment. Glasgow, Public Health Institute of Scotland, NHS Scotland (2002).
• Pincus, T., Yazici, Y., Sokka, T., Aletaha, D., Smolen, J.S.: Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis, Clin. Exp. Rheumatol., 21(Suppl 31), 179-85 (2003).
• Salliot, C., van der Heijde, D.: Long-term safety of methotrexate monotherapy in pa- tients with rheumatoid arthritis: a systematic literature research, Annals of the Rheu- matic Diseases, 68(7), 1100-4 (2009).
• Borchers, A.T., Keen, C.L., Cheema, G.S., Gershwin, M.E. The use of methotrexate in rheumatoid arthritis, Seminars in Arthritis and Rheumatism, 34(1), 465-83 (2004).
• Grove, M.L., Hassell, A.B., Hay, E.M., Shadforth, M.F. Adverse reactions to disease- modifying anti-rheumatic drugs in clinical practice, QJM, 94, 309-19 (2001).
• Montag, K., Gingold, M., Boers, A., Littlejohn, G. Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice, Internal Medicine Journal, 41(6), 450-5 (2011).
• Wluka, A., Buchbinder, R., Mylvaganam, A., Hall, S., Harkness, A., Lewis, D., et al. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice, Journal of Rheumatology, 27,1864-71 (2000).
• Ortendahl, M., Schettler, J.D., Fries, J.F. Factors influencing length of time taking methotrexate in rheumatoid arthritis, Journal of Rheumatology, 27, 1139-47 (2000).
• Maetzel, A., Wong, A., Strand, V., Tugwell, P., Wells, G., Bombardier, C.: Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease- modifying anti-rheumatic drugs, Rheumatology, 39,975-81 (2000).
• Turner, G., Symmons, D., Bamji, A., Palferman, T.: Consultant rheumatology workforce in the UK: changing patterns of provision 1997-2001, Rheumatology, 41, 680-4 (2002).
• Roberts, C., Adebajo, A.O., Long, S. Improving the quality of care of musculoskeletal conditions in primary care, Rheumatology, 41, 503-8 (2002).
• Singh, J.A., Furst, D.E., Bharat, A., Curtis, J.R., Kavanaugh, A.F., Kremer, J.M., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis, Arthritis Care & Research, 64(5),625-39 (2012).
• Gaujoux-Viala, C., Smolen, J.S., Landewé, R., Dougados, M., Kvien, T.K., Martin-Mola, E., et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis, Annals of Rheu- matic Diseases, 69, 1004-9 (2010).
• Smolen, J.S., Landewe, R., Breedveld, F.C., Dougados, M., Emery, P., Gaujoux-Viala, C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheu- matic Diseases, 69(6), 964-75 (2010).
• British Society for Rheumatology, The Research Unit of The Royal College of Physicians. Guidelines and audit measures for the specialist supervision of patients with rheuma- toid arthritis, Journal of the Royal College of Physicians of London, 26(1), 76-81 (1992).
• American College of Rheumatology Ad Hoc Committee on clinical guidelines. Guide- lines for the management of rheumatoid arthritis, Arthritis & Rheumatism, 39(5), 713- 22 (1996).
• Scottish Intercollegiate Guidelines Network (SIGN). Management of early rheumatoid arthritis, Edinburgh: SIGN; 2011. (SIGN publication no. 123).
• British Society for Rheumatology. National guidelines for the monitoring of second line drugs. London: British Society for Rheumatology, July 2000.
• Visser, K., Katchamart, W., Loza, E., Martinez-Lopez, J.A., Salliot, C., Trudeau, J., et al. Multinational evidence-based recommendations for the use of methotrexate in rheu- matic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Annals of the Rheumatic Diseases, 68(7), 1086-93 (2009).
• Pavy, S., Constantin, A., Pham, T., Gossec, L., Maillefert, J.F., Cantagrel, A., et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion, Joint Bone Spine : revue du rhumatisme, 73(4), 388-95 (2006).
• Katchamart, W., Bourre-Tessier, J., Donka, T., Drouin, J., Rohekar, G., Bykerk, V.P., et al. Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis, J. Rheumatol, 37(7), 1422-30 (2010).
• Campbell, S.M., Cantrill, J.A. Consensus methods in prescribing research, Interna- tional Journal of Clinical Pharmacy and Therapeutics, 26, 5-14 (2001).
• Hasson, F., Keeney, S., McKenna, H. Research guidelines for the Delphi survey tech- nique, Journal of Advanced Nursing, 32(4), 1008-15 (2000).
• Fink, A., Kosecoff, J., Chassin, M.R., Brook, R.H. Consensus Methods: Characteristics and Guidelines for Use. Santa Monica, CA: RAND (1991).
• Thompson, A.E., Bashook, P.G. Rheumatologists’ recommended patient information when prescribing methotrexate for rheumatoid arthritis, Clin. Exp. Rheumatol, 28(4), 539-45 (2010).
• Jones, J., Hunter, D. Qualitative research: consensus methods for medical and health services research, BMJ, 311, 376-80 (1995).
• Greatorex, J., Dexter, T. An accessible analytical approach for investigating what hap- pens between the rounds of a Delphi study, Journal of Advanced Nursing, 32(4),1016- 24 (2000).
• Murphy, M., Black, N., Lamping, D., McKee, C., Sanderson, C., Askham, J., et al. Con- sensus development methods, and their use in clinical guideline development, Health Technology Assessment, 2(3), (1998).